{"id":"placebo-spiriva-capsule","safety":{"commonSideEffects":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo Spiriva capsule","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:39:01.200115+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:39:06.979711+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo Spiriva capsule","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:39:07.301552+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1900528/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:39:08.192392+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"A placebo Spiriva capsule contains no active tiotropium or other therapeutic agent. It is used as a control in clinical trials to measure the effect of the active Spiriva formulation (tiotropium, a long-acting anticholinergic bronchodilator) against baseline or non-specific effects. Any observed benefit would be attributable to placebo response rather than drug mechanism.","oneSentence":"This is a placebo formulation with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:31.518Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T04:39:09.759609+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Clinical trial control for COPD and asthma studies"}]},"trialDetails":[{"nctId":"NCT05986591","phase":"PHASE3","title":"Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Xiromed LLC","startDate":"2022-08-17","conditions":"COPD","enrollment":335},{"nctId":"NCT02242266","phase":"PHASE2","title":"Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-07-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":121},{"nctId":"NCT00668772","phase":"PHASE3","title":"Tiotropium/Salmeterol Inhalation Powder in COPD","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":207},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT00662740","phase":"PHASE3","title":"Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":220},{"nctId":"NCT02203474","phase":"PHASE2","title":"A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease","status":"WITHDRAWN","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-08","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":""},{"nctId":"NCT01176903","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-08","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":65},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT03084796","phase":"PHASE2","title":"A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-07-28","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":733},{"nctId":"NCT02586649","phase":"PHASE2","title":"24hr Effects of Tiotropium Bromide in Tetraplegia","status":"COMPLETED","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2014-07","conditions":"Spinal Cord Injury","enrollment":10},{"nctId":"NCT04147572","phase":"NA","title":"Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2019-11-01","conditions":"Healthy Volunteer, COPD","enrollment":200},{"nctId":"NCT00569270","phase":"PHASE4","title":"Dynamic Hyperinflation and Tiotropium","status":"COMPLETED","sponsor":"Gelb, Arthur F., M.D.","startDate":"2006-10","conditions":"COPD","enrollment":30},{"nctId":"NCT02796677","phase":"PHASE3","title":"AMPLIFY - D6571C00001 Duaklir USA Phase III Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-07-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1595},{"nctId":"NCT02573155","phase":"PHASE1","title":"Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10","conditions":"Asthma (Part 1), COPD (Part 2)","enrollment":134},{"nctId":"NCT01662986","phase":"PHASE4","title":"Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-08-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":79},{"nctId":"NCT01663987","phase":"PHASE4","title":"Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-08-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":79},{"nctId":"NCT02172391","phase":"PHASE3","title":"Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":81},{"nctId":"NCT02172443","phase":"PHASE3","title":"Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":50},{"nctId":"NCT02172794","phase":"PHASE3","title":"Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":48},{"nctId":"NCT02257385","phase":"PHASE3","title":"Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":967},{"nctId":"NCT00157235","phase":"PHASE3","title":"Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":234},{"nctId":"NCT00152984","phase":"PHASE4","title":"Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-12","conditions":"Pulmonary Disease, Chronic Obstructive, Asthma","enrollment":472},{"nctId":"NCT01566773","phase":"PHASE2","title":"PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2012-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":140},{"nctId":"NCT00279019","phase":"PHASE1","title":"Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":31},{"nctId":"NCT00555022","phase":"PHASE1","title":"Effect of GSK1160724 In Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-12-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":21},{"nctId":"NCT00515502","phase":"PHASE2","title":"Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-21","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":24},{"nctId":"NCT01715311","phase":"PHASE4","title":"Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":""},{"nctId":"NCT01854645","phase":"PHASE3","title":"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":2103},{"nctId":"NCT01462929","phase":"PHASE3","title":"Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":414},{"nctId":"NCT01455129","phase":"PHASE4","title":"Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in China","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2011-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":841},{"nctId":"NCT01610037","phase":"PHASE3","title":"Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1215},{"nctId":"NCT01959516","phase":"PHASE4","title":"Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-02","conditions":"COPD","enrollment":124},{"nctId":"NCT00999908","phase":"PHASE3","title":"Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":54},{"nctId":"NCT01922271","phase":"PHASE4","title":"Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":152},{"nctId":"NCT01696058","phase":"PHASE3","title":"Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1137},{"nctId":"NCT02242240","phase":"PHASE2","title":"Lung Function Changes Following the Addition of Formoterol to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":95},{"nctId":"NCT02242253","phase":"PHASE2","title":"Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":97},{"nctId":"NCT01694771","phase":"PHASE3","title":"Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1134},{"nctId":"NCT02173691","phase":"PHASE3","title":"Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":584},{"nctId":"NCT02172300","phase":"PHASE3","title":"Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":198},{"nctId":"NCT02172508","phase":"PHASE4","title":"Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2004-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":15},{"nctId":"NCT02172469","phase":"PHASE3","title":"Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":215},{"nctId":"NCT02172807","phase":"PHASE3","title":"Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":201},{"nctId":"NCT02172287","phase":"PHASE3","title":"Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":623},{"nctId":"NCT02172781","phase":"PHASE1","title":"Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-01","conditions":"Healthy","enrollment":36},{"nctId":"NCT02172378","phase":"PHASE3","title":"12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":116},{"nctId":"NCT01126437","phase":"PHASE3","title":"Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":17183},{"nctId":"NCT01574651","phase":"PHASE3","title":"The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":934},{"nctId":"NCT00523991","phase":"PHASE4","title":"Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":457},{"nctId":"NCT00144339","phase":"PHASE3","title":"Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":5993},{"nctId":"NCT01613326","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":657},{"nctId":"NCT01490125","phase":"PHASE3","title":"The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":247},{"nctId":"NCT01072396","phase":"PHASE4","title":"Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":126},{"nctId":"NCT00274573","phase":"PHASE3","title":"Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1639},{"nctId":"NCT00281567","phase":"PHASE3","title":"Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":76},{"nctId":"NCT00274547","phase":"PHASE3","title":"Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1829},{"nctId":"NCT00239460","phase":"PHASE3","title":"Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":196},{"nctId":"NCT00274066","phase":"PHASE3","title":"Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":65},{"nctId":"NCT00106821","phase":"PHASE4","title":"Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":166},{"nctId":"NCT00144326","phase":"PHASE3","title":"A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":250},{"nctId":"NCT00274079","phase":"PHASE4","title":"SPIRIVA in Ususal Care","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":395},{"nctId":"NCT01202188","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":2144},{"nctId":"NCT00929110","phase":"PHASE3","title":"1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1066},{"nctId":"NCT00578968","phase":"PHASE4","title":"Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-10","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":36},{"nctId":"NCT00877383","phase":"PHASE3","title":"Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-04","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1142},{"nctId":"NCT00900731","phase":"PHASE3","title":"A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1598},{"nctId":"NCT00846586","phase":"PHASE3","title":"Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1134},{"nctId":"NCT00463567","phase":"PHASE2, PHASE3","title":"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-04","conditions":"Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive","enrollment":2059},{"nctId":"NCT00680056","phase":"PHASE4","title":"Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2007-11","conditions":"Pulmonary Disease, Chronic Obstructive, Chronic Bronchitis, Pulmonary Emphysema","enrollment":33},{"nctId":"NCT00405236","phase":"PHASE4","title":"Effect of Tiotropium on Inflammation and Exacerbations in COPD","status":"COMPLETED","sponsor":"Royal Free and University College Medical School","startDate":"2002-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1900528"},"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tiotropium Bromide","Tiotropium 18 µg","LAMA","tiotropium bromide"],"phase":"marketed","status":"active","brandName":"Placebo Spiriva capsule","genericName":"Placebo Spiriva capsule","companyName":"Orion Corporation, Orion Pharma","companyId":"orion-corporation-orion-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo formulation with no active pharmacological mechanism. Used for Clinical trial control for COPD and asthma studies.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T04:39:09.759609+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}